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Expression of CD90 on keratinocyte stem or 
progenitor cells
Keratinocyte stem cells (KSCs) 
are capable of self-renewal, 
and identification, purifica-
tion and maintenance of dif-
ferentiating cell populations 
could lead to significant clini-
cal applications, such as the 
culturing of keratinocytes for 
transplantation to severe burn wounds. Using in vitro and in 
vivo assays, Nakamura et al. have demonstrated that the cell-
surface marker CD90 recognizes human KSC-enriched popula-
tions in cultured keratinocytes. The use of this marker provides 
a simple and rapid method for detecting human keratinocyte 
stem or progenitor cells for tissue engineering applications. Br J 
Dermatol 2006; 154: 1062–1070.
Dopamine-induced apoptosis in human 
melanocytes involves generation of reactive 
oxygen species
Previous studies have 
shown that significant 
increases in urinary 
and plasma levels of 
several monoamines 
and their metabo-
lites characterize the 
onset of vitiligo and 
its progression. Both 
epidermal keratino-
cytes and melano-
cytes were found to have the capacity for the biosynthesis of 
several catecholamines and serotonin. Chu et al. found that 
dopamine decreased the melanocyte viability dose-depend-
ently at concentrations ranging from 0.01 to 100 μmol L-1. 
Dopamine also induced melanocyte apoptosis, which might 
be related to the generation of reactive oxygen species. This 
novel effect might play an important role in the develop-
ment or progression of vitiligo, which is currently viewed as 
a disease process closely related to melanocyte apoptosis. Br J 
Dermatol 2006; 154:1071–1079.
Significance of interleukin-16, macrophage-
derived chemokine, eosinophil cationic protein 
and soluble E-selectin in reflecting disease 
activity of atopic dermatitis – from laboratory 
parameters to clinical scores
A major difficulty in assessing the relevance of laboratory mark-
ers of AD severity is the use of nonvalidated reference tools. 
In the present study the 
serum levels of IL-16, MDC, 
sE-selectin and ECP were 
compared against the same 
reference score (SCORAD) 
in the same time frame and 
group of adult patients with 
AD. The serum levels of all 
parameters were signifi-
cantly higher in the acute stage of AD and decreased parallel 
to clinical improvement. The most consistent correlation to 
SCORAD was found for IL-16. Furthermore, Angelova-Fischer 
et al. found significant correlation between the serum levels of 
IL-16 and MDC. Br J Dermatol 2006; 154:1112–1117.
A 52-week randomized safety study of 
calcipotriol/betamethasone dipropionate 
two-compound product (Dovobet®/Daivobet®) 
in the treatment of psoriasis vulgaris
The calcipotriol/beta-
methasone dipropionate 
two-compound prod-
uct Dovobet®/Daivobet® 
(LEO Pharma) has been 
shown to be safe and 
effective in the treatment 
of psoriasis for up to 8 weeks. In this study, 634 patients were 
randomized to one of two treatment regimens involving use 
of the two-compound product over 52 weeks, or to a control 
group. Treatment with the two-compound product for up to 52 
weeks appears to be safe and well tolerated whether used on its 
own or alternating every 4 weeks with calcipotriol treatment. 
Br J Dermatol 2006; 154:1155–1160.
Improvement in quality of life with infliximab 
induction and maintenance therapy in 
patients with moderate-to-severe psoriasis: a 
randomized controlled trial
Reich et al. evaluated the effect of infliximab on the 
health-related quality of life (HRQoL) of 378 patients with 
moderate-to-severe psoriasis in the randomized, placebo-con-
trolled EXPRESS study. Patients receiving infliximab showed 
rapid and clinically meaningful improvement in DLQI scores 
and SF-36 summary and scale scores, including vitality and 
mental health, at week 10. Improvement was maintained 
through week 24 and remained substantial through week 54. 
The percentage of infliximab-treated patients indicating that 
psoriasis had ‘no effect’ on HRQoL increased from 2.7% (base-
line) to 65.9% (week 24; Figure). This study demonstrates the 
long-term improvement in HRQoL among psoriasis patients 
treated with infliximab. Br J Dermatol 2006; 154:1161–1168.
